These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35535145)
1. CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma. Liu L; Hui R; Zeng T; Yang X; Wu Q; Yang T Int J Gen Med; 2022; 15():4613-4623. PubMed ID: 35535145 [TBL] [Abstract][Full Text] [Related]
2. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma]. Mei W; Wang XM; Liu RA; Xiong W; Zhang YP Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988 [No Abstract] [Full Text] [Related]
3. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma]. Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421 [No Abstract] [Full Text] [Related]
4. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker. Lin P; Zhao Y; Li X; Liang Z Comb Chem High Throughput Screen; 2022; 25(9):1498-1506. PubMed ID: 34238152 [TBL] [Abstract][Full Text] [Related]
12. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells. Kuramitsu Y; Tominaga W; Baron B; Tokuda K; Wang Y; Kitagawa T; Nakamura K Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908 [TBL] [Abstract][Full Text] [Related]
13. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535 [TBL] [Abstract][Full Text] [Related]
15. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960 [TBL] [Abstract][Full Text] [Related]
16. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049 [TBL] [Abstract][Full Text] [Related]
17. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. Brockwell NK; Alamgeer M; Kumar B; Rivalland G; John T; Parker BS Transl Lung Cancer Res; 2020 Jun; 9(3):639-645. PubMed ID: 32676326 [TBL] [Abstract][Full Text] [Related]
18. The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma. Oguh-Olayinka L; Agarwal V; Ranatunge D; Campbell A; Laufer S; Cawkwell L; Lind MJ Pathol Oncol Res; 2020 Apr; 26(2):985-995. PubMed ID: 30941737 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma. Walter RFH; Sydow SR; Berg E; Kollmeier J; Christoph DC; Christoph S; Eberhardt WEE; Mairinger T; Wohlschlaeger J; Schmid KW; Mairinger FD Cancer Manag Res; 2019; 11():8711-8720. PubMed ID: 31576173 [TBL] [Abstract][Full Text] [Related]